Skip to main content

Advertisement

Table 2 Statistical analysis of 111In-PSMA-617 and 111In-RM2 bindings according to clinico-biological parameters (pathological size, Gleason score, prostate-specific antigen (PSA) value, and metastatic risk). Non-parametric one-way ANOVA (Kruskal-Wallis test) and non-parametric t test (Wilcoxon test). p <  0.05 was considered significant

From: Comparison of the radiolabeled PSMA-inhibitor 111In-PSMA-617 and the radiolabeled GRP-R antagonist 111In-RM2 in primary prostate cancer samples

Biological parameters n 111In-PSMA-617 111In-RM2 p value
Pathological size
 pT2 8 66.00 ± 3.65% 9.17 ± 2.17% 0.0078
 pT3&4 11 54.82 ± 4.45% 2.82 ± 1.28% 0.0010
p value   0.105 0.161  
Gleason score
 6 5 64.60 ± 4.83% 14.67 ± 3.96% 0.0625
 7 12 54.50 ± 4.87% 2.58 ± 1.19% 0.0005
 8–9 3 62.33 ± 8.73% 0.0 ± 0.0% 0.0065
p value   0.5554 0.0019  
PSA value
 < 10 ng/mL 5 64.60 ± 4.83% 14.67 ± 3.96% 0.0625
 ≥ 10 ng/mL 15 56.07 ± 4.04% 2.07 ± 0.98% < 0.0001
p value   0.404 0.0012  
Metastatic risk
 Low 5 64.60 ± 4.83% 14.67 ± 3.96% 0.0625
 Intermediate 7 58.86 ± 4.90% 2.86 ± 1.86% 0.0156
 High 8 53.63 ± 6.44% 1.38 ± 0.94% 0.0078
p value   0.665 0.0046  
Total 20 58.2 ± 14.82% 5.2 ± 7.65% < 0.0001